SCA
TVTX icon

Snowden Capital Advisors’s Travere Therapeutics TVTX Stock Holding History

Snowden Capital Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$204K Sell
6,859
-335
-5% -$10K 0.01% 1216
2025
Q4 		$275K Buy
+7,194
New +$234K 0.01% 1077

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Snowden Capital Advisors's TVTX Position: Q1 2026 in Review

Snowden Capital Advisors reduced its Travere Therapeutics (TVTX) stake by 4.7% in Q1 2026, selling an estimated $10K and leaving 6,859 shares worth $204K. The position accounts for 0.01% of the portfolio, ranked #1216.

Snowden Capital Advisors first reported a position in TVTX in Q4 2025 and has held it in 2 quarters since. The position peaked at $275K in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Snowden Capital Advisors held 6,859 shares of Travere Therapeutics worth $204K as of Q1 2026.
  • Snowden Capital Advisors sold 335 Travere Therapeutics shares in Q1 2026, an estimated $10K.
  • Travere Therapeutics made up 0.01% of Snowden Capital Advisors's portfolio in Q1 2026, its #1216 holding.
  • Snowden Capital Advisors first reported a position in Travere Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Snowden Capital Advisors's Travere Therapeutics position peaked at $275K in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Snowden Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.